It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone ...

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...

Danish drugmaker Novo Nordisk’s injectable semaglutide – sold under brand names Ozempic and Wegovy –may also be launched in India sometime this year. The innovator hasn’t clarified a ...

A recent clinical trial, led by UNC School of Medicine researchers Dr. John Buse and Dr. Matthew Cavender, found that the oral form of semaglutide significantly reduces the risk of cardiovascular ...

Novo Nordisk’s oral semaglutide tablet, Rybelsus, launched in India in January 2022, has already captured nearly 65% of the anti-obesity drug market along with other weight loss medications ...

[i] Rybelsus (semaglutide) tablets are FDA-approved for oral use and were not in shortage. The FDA’s February Declaratory order specifically addresses the compounding of semaglutide injection ...

Half of the participants took a semaglutide tablet daily and half took a placebo. Participants continued their assigned regimen for an average of just under four years. By the end of the trial ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...